Transgene announced that its management team will meet institutional investors during the Investor Access Event in Paris on October 6, 2026. The biotech firm will discuss progress on its myvac individualized neoantigen therapeutic vaccines (INTV) platform and virus-based candidates.

Organized by Investor Access, the event connects listed companies with professional investors through targeted, pre-arranged meetings. The 2026 program brings together more than 190 professional investors and 90 listed companies across its events.

Clinical Pipeline Focus

During the event, Transgene will highlight developments within its core clinical-stage programs. Key topics include the myvac platform assets:

• TG4050: Currently in development for head and neck cancer.
• TG4070: In Phase 1 clinical development for non-small cell lung cancer (NSCLC).

The company will also address other virus-based programs from its emerging pipeline. Transgene is a biotechnology company focused on designing and developing virus-based targeted immunotherapies and vaccines.

About Transgene

Transgene’s lead asset, TG4050, is the first INTV based on the myvac platform and has demonstrated clinical proof of principle in the adjuvant treatment of head and neck cancer. TG4070 introduces proprietary AI-driven neoantigen selection and scalable cell-line manufacturing capabilities.

Additional viral vector-based assets include BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. The company also conducts innovative discovery and preclinical work aimed at developing novel viral vector-based modalities.

Transgene reported a net loss of €15.7 million for the first half of 2026, narrowing from €19.3 million in the same period last year. The French biotech firm maintained cash visibility through early 2028 while advancing its individualized neoantigen therapeutic vaccines (INTV) platform.

Pipeline advancements and clinical milestones

The company highlighted significant progress in its lead asset, TG4050, an INTV for resected head and neck squamous cell carcinoma (HNSCC). Comprehensive Phase 1 results published in Nature Communications confirmed 100% disease-free survival (DFS) in treated patients after more than three years of follow-up. In contrast, three of 16 patients in the control arm experienced relapse. Patient randomization for the Phase 2 trial is complete, with topline results expected in Q1 2028.

Transgene also initiated a randomized Phase 1 trial for TG4070, its second INTV candidate targeting non-small cell lung cancer (NSCLC). This program leverages the company’s proprietary AI-driven neoantigen selection tool, SNIPER™, and scalable cell-line manufacturing processes.

Strategic partnerships and manufacturing

To support TG4050’s development, Transgene signed a license agreement with NEC Bio B.V. for access to AI-based neoantigen prediction technology. The deal involved a €2.5 million fee paid in shares and a €1.0 million initial cash payment, with the remainder of the €2.5 million cash component payable in installments through early 2028.

The company is transitioning TG4050 to cell-line based manufacturing to prepare for potential pivotal trials and broader commercial scalability.

Financial performance

Operating income declined to €3.0 million from €4.6 million in H1 2025, driven primarily by a reduction in Research Tax Credit income to €2.5 million. R&D expenses fell to €15.4 million, while general and administrative costs rose slightly to €4.1 million.

As of June 30, 2026, the company held €92.8 million in cash and equivalents, down from €111.9 million at the end of 2025. Cash burn increased to €20.3 million from €18.8 million in the prior year period.

What the numbers show

While operating income dropped by 34.6%, the net loss narrowed by 18.8%, indicating that the improvement in financial income (swinging from a loss of €2.2 million to income of €1.1 million) partially offset the decline in operational revenue. The increase in cash burn despite lower R&D spending suggests higher working capital requirements or financing activities not fully detailed in the summary, though the company maintains sufficient liquidity for operations until early 2028.